Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The outcome comparison of low- and medium-dose immune tolerance induction therapy using domestic recombinant coagulation factor VIII in severe hemophilia A children with high titer inhibitor: a randomized controlled clinical trial

Next Previous
Search
Trial Profile

The outcome comparison of low- and medium-dose immune tolerance induction therapy using domestic recombinant coagulation factor VIII in severe hemophilia A children with high titer inhibitor: a randomized controlled clinical trial

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omfiloctocog alfa (Primary) ; Prednisone; Rituximab
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms LOME

    • Most Recent Events

    • 18 Jan 2023 New trial record
    • 13 Dec 2022 Results (n=10) for protocol and primary analysis of Lome study, presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top